凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002821 凯莱英

交易中 07-23 10:39:27

{"stockData":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":69.05,"timestamp":1721702367000,"preClose":69.35,"halted":0,"volume":1333800,"delay":0,"floatShares":329000000,"shares":369000000,"eps":5.1978,"marketStatus":"交易中","marketStatusCode":2,"change":-0.3,"latestTime":"07-23 10:39:27","open":68.72,"high":69.58,"low":68.61,"amount":92038800,"amplitude":0.014,"askPrice":69.07,"askSize":3,"bidPrice":69.06,"bidSize":12,"shortable":0,"etf":0,"ttmEps":5.1978,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1721705400000},"adr":0,"adjPreClose":69.35,"symbolType":"stock","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":76.29,"lowLimit":62.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":369471533,"pbRate":1.46,"roa":"--","roe":"1.6%","epsLYR":6.26,"committee":0.227273,"marketValue":25512000000,"floatMarketCap":22686000000,"peRate":13.284466,"changeRate":-0.0043,"turnoverRate":0.0041,"status":1},"requestUrl":"/m/hq/s/002821/wiki","defaultTab":"wiki","newsList":[{"id":"2452740004","title":"凯莱英(06821)参与投资基金完成私募投资基金备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2452740004","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452740004?lang=zh_cn&edition=full","pubTime":"2024-07-19 22:23","pubTimestamp":1721399012,"startTime":"0","endTime":"0","summary":"凯莱英(06821)公布，公司于2024年4月29 \n日召开第四届董事会第五十次会...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_20.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_20.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1328615791.USD","BK1191","BK0239","BK0132","002821","06821"],"gpt_icon":0},{"id":"2452426179","title":"摩根大通减持凯莱英(06821)28.04万股 每股作价约45.57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452426179","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452426179?lang=zh_cn&edition=full","pubTime":"2024-07-19 18:10","pubTimestamp":1721383800,"startTime":"0","endTime":"0","summary":"香港联交所数据显示，7月15日，摩根大通减持凯莱英(06821)28.04万股，每股作价45.5702港元，总金额约1277.79万港元。减持后最新持股数目约为407.05万股，持股比例为14.77%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-19/doc-incesnuw5332007.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-19/doc-incesnuw5332007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4566","LU0070302665.USD","BK0132","LU1668664300.SGD","IE00BLSP4452.SGD","LU1496350502.SGD","LU1244550494.USD","LU1244550577.SGD","LU0234572021.USD","BK4207","LU1328615791.USD","LU0976567544.SGD","LU1267930490.SGD","BK4588","BK4534","LU0211326755.USD","LU1032466523.USD","LU1670627923.USD","BK4550","BK0239","LU0238689110.USD","LU1496350171.SGD","06821","LU1363072403.SGD","LU0149725797.USD","IE00BKVL7J92.USD","LU","LU1261432733.SGD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","LU0496365809.HKD","IE00BWXC8680.SGD","LU1162221912.USD","LU0320765489.SGD","LU1670628061.USD","LU0211326839.USD","002821","LU0208291251.USD","LU0170899867.USD","LU1084165304.USD","LU0417517546.SGD","IE00BLSP4239.USD","BK4585","LU0882574139.USD","IE00B1BXHZ80.USD","LU0971096721.USD","BK4516","BK1191","BK4533","LU1119994496.HKD"],"gpt_icon":0},{"id":"2452904606","title":"凯莱英(06821)上涨5.19%，报47.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452904606","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452904606?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:04","pubTimestamp":1721192647,"startTime":"0","endTime":"0","summary":"7月17日，凯莱英(06821)盘中上涨5.19%，截至13:04，报47.6元/股，成交1387.54万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年一季报，凯莱英营业总收入13.64亿元、净利润2.82亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/17130441615421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","002821","LU1328615791.USD","BK0239","BK0132","06821"],"gpt_icon":0},{"id":"2452904521","title":"凯莱英(06821)股价上升5.193%，现价港币$47.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2452904521","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452904521?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:04","pubTimestamp":1721192640,"startTime":"0","endTime":"0","summary":"[上升股]凯莱英(06821) 股价在下午01:04比前收市价上升5.193%，现股价为港币$47.6。至目前为止，今日最高价为$47.6，而最低价为$45.65。总成交量为29.66万股，总成交金额为港币$1.387千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240717959/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","LU1328615791.USD","002821","BK0239","06821","BK0132"],"gpt_icon":0},{"id":"2450497573","title":"凯莱英（002821）7月11日主力资金净买入1197.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450497573","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450497573?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:12","pubTimestamp":1720746740,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月11日收盘，凯莱英报收于66.52元，上涨7.97%，换手率2.24%，成交量7.35万手，成交额4.81亿元。近5日资金流向一览见下表：凯莱英融资融券信息显示，融资方面，当日融资买入3201.32万元，融资偿还3518.68万元，融资净偿还317.36万元。凯莱英主营业务：是一家全球领先、技术驱动型的医药外包服务一站式综合服务商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200013635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","002821","LU1328615791.USD","BK0239","BK0132","06821"],"gpt_icon":0},{"id":"2450287740","title":"凯莱英(06821)上涨5.03%，报47.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450287740","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450287740?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:09","pubTimestamp":1720663754,"startTime":"0","endTime":"0","summary":"7月11日，凯莱英盘中上涨5.03%，截至10:09，报47.0元/股，成交876.64万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。截至2024年一季报，凯莱英营业总收入13.64亿元、净利润2.82亿元。7月10日，预计2024年中报业绩预减，归属股东应占溢利约4.8亿人民币至5.5亿人民币，同比下降67.39%至71.54%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/11100941504885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","LU1328615791.USD","06821","002821","BK0239","BK0132"],"gpt_icon":0},{"id":"2450845266","title":"《盈警》凯莱英(06821.HK)预计上半年利润大减67%-71.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450845266","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450845266?lang=zh_cn&edition=full","pubTime":"2024-07-11 01:24","pubTimestamp":1720632240,"startTime":"0","endTime":"0","summary":"凯莱英发盈警，预计6月止六个月净利润介乎4.8亿至5.5亿人民币，较2023年同期减少67.4%-71.5%。主要因去年同期交付的大订单毛利率较高；新兴业务毛利率较低；及公司严格控制各项成本费用，但难以在短时间内实现与收入降幅保持同步调整。期间，营业收入预计介乎26.6亿至27.4亿人民币，下降40.7%-42.5%。沽空资料截至 2024-07-10 16:25。)过往派息公布日期派息事项派息内容2024/04/25第一季业绩无派息2024/03/28末期业绩普通股息：人民币 1.8 2023/10/30第三季业绩无派息2023/08/29中期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180419153629820_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180419153629820_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362791/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0132","BK1191","002821","06821","LU1328615791.USD","BK0239"],"gpt_icon":0},{"id":"2450444938","title":"凯莱英：预计2024年上半年归属于上市公司股东的净利润为4.80亿元-5.50亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450444938","media":"金融界港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450444938?lang=zh_cn&edition=full","pubTime":"2024-07-10 22:35","pubTimestamp":1720622116,"startTime":"0","endTime":"0","summary":"金融界7月10日消息，凯莱英发布2024年半年业绩预告，预计2024年上半年归属于上市公司股东的净利润为4.80亿元-5.50亿元，与上年同期比下降67.39%-71.54%；营业收入预计为26.60亿元-27.40亿元，比上年同期下降40.72%-42.45%。下降主要原因为去年同期交付大订单，今年不再有相关订单、新兴业务收入下降以及部分业务处于爬坡期导致产能利用率相对较低。公司仍对未来有信心，在新技术研发投入和新业务培育方面继续保持，并加大海外布局以及多肽产能建设。另据凯莱英表示，此次业绩预告由公司财务部门预测，未经会计师事务所预审计。\n\n\r\n            责任编辑：山上","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/10223541499331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06821","002821"],"gpt_icon":0},{"id":"2450189018","title":"凯莱英(06821)预期上半年营业收入约26.60亿元至27.40亿元 同比下降40.72%至42.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450189018","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450189018?lang=zh_cn&edition=full","pubTime":"2024-07-10 21:42","pubTimestamp":1720618922,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英 发布公告，该集团预期2024年1月1日至2024年6月30日(报告期)归属于公司股东的净利润约人民币4.8亿元至5.5亿元，同比减少约67.39%至71.54%。2024年上半年，公司实现营业收入约26.60亿元至27.40亿元，同比下降40.72%至42.45%，主要系去年同期交付大订单，今年无相关订单所致。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06821","002821"],"gpt_icon":0},{"id":"2450818805","title":"凯莱英(06821)：2021年A股股权激励计划首次授予的回购价格调整为每股128.34元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450818805","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450818805?lang=zh_cn&edition=full","pubTime":"2024-07-10 21:32","pubTimestamp":1720618375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布公告，2021年A股股权激励计划首次授予的回购价格由每股人民币130.14元调整为每股人民币128.34元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1328615791.USD","159982","002821","06821","BK0132","BK1191","399300"],"gpt_icon":0},{"id":"2450890606","title":"凯莱英(06821)：2020年受限制A股股权激励计划回购价格调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2450890606","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450890606?lang=zh_cn&edition=full","pubTime":"2024-07-10 21:25","pubTimestamp":1720617953,"startTime":"0","endTime":"0","summary":"凯莱英(06821)发布公告，根据2023年度利润分配方案，公司以利润分配登记日期...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_46.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_46.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0132","BK0239","399300","159982","LU1328615791.USD","06821","BK1191","002821"],"gpt_icon":0},{"id":"2450892662","title":"凯莱英(002821.SZ)发预减，预计上半年净利润4.8亿元至5.5亿元 下降67.39%-71.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450892662","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450892662?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:56","pubTimestamp":1720616205,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(002821.SZ)发布2024年半年度业绩预告，预计上半年归属于上市公司股东的净利润4.8亿元至5.5亿元，同比下降67.39%-71.54%。上半年，公司实现营业收入26.60亿元-27.40亿元，同比下降40.72%-42.45%，主要系去年同期交付大订单，今年不再有相关订单所致。报告期内，在境内外生物医药融资环境持续低迷的情况下，公司营业收入剔除上年同期大订单影响后实现微幅增长，其中，小分子CDMO业务剔除大订单影响后同比仍保持正增长;新兴业务收入主要受国内生物医药融资复苏不及预期，营业收入同比下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","002821"],"gpt_icon":0},{"id":"2450896013","title":"凯莱英：预计2024年1-6月归属净利润盈利4.8亿元至5.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450896013","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450896013?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:02","pubTimestamp":1720612929,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英发布业绩预告，预计2024年1-6月归属净利润盈利4.8亿元至5.5亿元。公告中解释本次业绩变动的原因为：2024年上半年,公司实现营业收入26.60亿元-27.40亿元,同比下降40.72%-42.45%,主要系去年同期交付大订单,今年不再有相关订单所致。凯莱英2024年一季报显示，公司主营收入14.0亿元，同比下降37.76%；归母净利润2.82亿元，同比下降55.27%；扣非净利润2.54亿元，同比下降58.88%；负债率11.26%，投资收益907.11万元，财务费用-7830.82万元，毛利率43.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000042463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","002821"],"gpt_icon":0},{"id":"2450951488","title":"凯莱英最新公告：预计上半年净利同比下降67.39%-71.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450951488","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450951488?lang=zh_cn&edition=full","pubTime":"2024-07-10 19:39","pubTimestamp":1720611560,"startTime":"0","endTime":"0","summary":"凯莱英公告，预计上半年净利4.8亿元-5.5亿元，同比下降67.39%-71.54%。报告期内，在境内外生物医药融资环境持续低迷的情况下，公司营业收入剔除上年同期大订单影响后实现微幅增长。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000041327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK1191","BK0239","LU1328615791.USD","002821","06821"],"gpt_icon":0},{"id":"2450898813","title":"凯莱英：公司大股东及董监高目前无减持计划，且均未开展转融通业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2450898813","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450898813?lang=zh_cn&edition=full","pubTime":"2024-07-10 19:01","pubTimestamp":1720609266,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英07月10日在投资者关系平台上答复投资者关心的问题。我虽看好价值，但公司高管自2018年以来频繁减持公司股票在投资者看来他们根本没有用心管理经营公司！请公司关闭转融通出借股份，用心经营管理公司，做大做强！公司大股东及董监高目前无减持计划，且均未开展转融通业务。公司管理层勤勉履职，聚焦公司主营业务发展，致力于提升公司综合竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000039379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","LU1328615791.USD","BK0239","06821","002821","BK0132"],"gpt_icon":0},{"id":"2449748558","title":"凯莱英(06821)下跌5.06%，报45.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449748558","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449748558?lang=zh_cn&edition=full","pubTime":"2024-07-08 13:00","pubTimestamp":1720414848,"startTime":"0","endTime":"0","summary":"7月8日，凯莱英(06821)盘中下跌5.06%，截至13:00，报45.0元/股，成交641.16万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年一季报，凯莱英营业总收入13.64亿元、净利润2.82亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08130041426996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","LU1328615791.USD","002821","BK0239","06821","BK0132"],"gpt_icon":0},{"id":"2449640288","title":"上市不到四年市值缩水九成，凯莱英（06821）基本面恶化了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2449640288","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449640288?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:47","pubTimestamp":1720144070,"startTime":"0","endTime":"0","summary":"四个月斥资回购10个亿，仍止不住持续下跌的股价，全球领先CDMO公司，凯莱英（06821）为何惨遭投资者抛弃？","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240705/20240705095013_40797.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240705/20240705095013_40797.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1328615791.USD","BK0132","BK1191","002821","06821","BK0239"],"gpt_icon":0},{"id":"2448838999","title":"凯莱英(06821)截至6月末累计回购约1230.07万股A股 涉资近10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448838999","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448838999?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:40","pubTimestamp":1719834031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)公布A股回购进展，截至2024年6月28日，公司累计通过回购专用证券账户以集中竞价方式回购公司股份数量为约1230.07万股，占公司A股总股本的3.5976%，最高成交价为102.00元/股，最低成交价为71.65元/股，合计支付的总金额为约9.996亿元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0239","LU1328615791.USD","002821","399300","159982","06821","BK0132"],"gpt_icon":0},{"id":"2448067996","title":"凯莱英(002821.SZ)已累计回购3.6%股份 耗资约10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448067996","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448067996?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:39","pubTimestamp":1719833945,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(002821.SZ)发布公告，截至2024年6月28日，公司累计通过回购专用证券账户以集中竞价方式回购公司股份数量为1230.07万股，占公司A股总股本的3.5976%，最高成交价为102.00元/股，最低成交价为71.65元/股，合计支付的总金额为10亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","BK0132","BK1191","002821","06821","BK0239"],"gpt_icon":0},{"id":"2446357610","title":"凯莱英最新公告：拟变更部分募投项目投资金额 并将调减募集资金投入至新增募投项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2446357610","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446357610?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:40","pubTimestamp":1719394826,"startTime":"0","endTime":"0","summary":"本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600036099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1328615791.USD","002821","06821","BK0132","BK1191"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-18","address":"天津市滨海新区经济技术开发区洞庭三街6号","stockEarnings":[{"period":"1week","weight":0.0749},{"period":"1month","weight":0},{"period":"3month","weight":-0.0768},{"period":"6month","weight":-0.262},{"period":"1year","weight":-0.3956},{"period":"ytd","weight":-0.3863}],"companyName":"凯莱英医药集团(天津)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"36947万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":"　　凯莱英医药集团(天津)股份有限公司是一家全球领先的服务于新药研发和生产的CDMO一站式综合服务商。为国内外大中型制药企业、生物技术公司提供高效和高质量的研发与生产服务，助推创新药的临床研究与商业化应用。主要包括临床阶段药品、商业化阶段药品、技术服务。公司是全球第五大创新药原料药CDMO公司，约占据1.5%的市场份额（第一名市场份额约为2.9%）；是中国最大的商业化阶段化学药物CDMO公司，约占据22%的市场份额。","serverTime":1721702368325,"listedPrice":30.53,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,002821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}